Platinum-based chemotherapy (CT) and its combination with HER-2/VEGFR-targeted therapy were the standard first-line systemic treatment options for patients with advanced G/GEJ adenocarcinoma (3–6). This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.